Abstract
The purpose of this study was to determine whether combining different testing modalities namely β-hexosaminidase A (HEXA) enzyme analysis, HEXA DNA common mutation assay, and HEXA gene sequencing could improve the sensitivity for carrier detection in non-Ashkenazi (AJ) individuals. We performed a HEXA gene sequencing assay, a HEXA DNA common mutation assay, and a HEXA enzyme assay on 34 self-reported Tay-Sachs disease (TSD) carriers, six late-onset patients with TSD, and one pseudodeficiency allele carrier. Sensitivity of TSD carrier detection was 91% for gene sequencing compared with 91% for the enzyme assay and 52% for the DNA mutation assay. Gene sequencing combined with enzyme testing had the highest sensitivity (100%) for carrier detection. Gene sequencing detected four novel mutations, three of which are predicted to be disease causing [118.delT, 965A→T (D322V), and 775A→G (T259A)]. Gene sequencing is useful in identifying rare mutations in patients with TSD and their families, in evaluating spouses of known carriers for TSD who have indeterminate enzyme analysis and negative for common mutation analysis, and in resolving ambiguous enzyme testing results.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- HEXA:
-
β-hexosaminidase A
- HEXB:
-
hexosaminidase B
- HEXP:
-
hexosaminidase P
- MUG:
-
4-methlyumbelliferyl-β-N-acetyl glucosaminide
- TSD:
-
Tay-Sachs Disease
References
Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K 1993 Tay-Sachs disease—carrier screening, prenatal diagnosis, and the molecular era. An international perspective 1970 to 1993. The International TSD Data Collection Network. JAMA 270: 2307–2315
ACOG Committee on Genetics 2005 ACOG committee opinion. Number 318, October 2005. Screening for Tay-Sachs disease. Obstet Gynecol 106: 893–894
O'Brien JS, Okada S, Chen A, Fillerup DL 1970 Tay-sachs disease. Detection of heterozygotes and homozygotes by serum hexosaminidase assay. N Engl J Med 283: 15–20
Bach G, Tomczak J, Risch N, Ekstein J 2001 Tay-Sachs screening in the Jewish Ashkenazi population: DNA testing is the preferred procedure. Am J Med Genet 99: 70–75
Navon R, Mark Z, Mashiah S, Padeh B 1973 Determination of Tay-Sachs genotypes in pregnant women. Clin Genet 4: 286–287
Nitowsky HM, Davis J, Nakagawa S, Fox D 1979 Human hexosaminidase isozymes. IV. Effects of oral contraceptive steroids on serum hexosaminidase activity. Am J Obstet Gynecol 134: 642–647
Cao Z, Natowicz MR, Kaback MM, Lim-Steele JS, Prence EM, Brown D, Chabot T, Triggs-Raine BL 1993 A second mutation associated with apparent beta-hexosaminidase A pseudodeficiency: identification and frequency estimation. Am J Hum Genet 53: 1198–1205
Triggs-Raine BL, Mules EH, Kaback MM, Lim-Steele JS, Dowling CE, Akerman BR, Natowicz MR, Grebner EE, Navon R, Welch JP, Greenberg CR, Thomas GH, Gravel RA 1992 A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening. Am J Hum Genet 51: 793–801
Kytzia HJ, Sandhoff K 1985 Evidence for two different active sites on human beta-hexosaminidase A. Interaction of GM2 activator protein with beta-hexosaminidase A. J Biol Chem 260: 7568–7572
Rozenberg R, Kok F, Burin MG, Sa Miranda MC, Vasques C, Henriques-Souza AM, Giugliani R, Vainzof M, Pereira LV 2006 Diagnosis and molecular characterization of non-classic forms of Tay-Sachs disease in Brazil. J Child Neurol 21: 540–544
Grebner EE, Tomczak J 1991 Distribution of three alpha-chain beta-hexosaminidase A mutations among Tay-Sachs carriers. Am J Hum Genet 48: 604–607
Triggs-Raine BL, Feigenbaum AS, Natowicz M, Skomorowski MA, Schuster SM, Clarke JT, Mahuran DJ, Kolodny EH, Gravel RA 1990 Screening for carriers of Tay-Sachs disease among Ashkenazi Jews. A comparison of DNA-based and enzyme-based tests. N Engl J Med 323: 6–12
Huang D, Chen C, Sun W, Strom CM, Bender RA 2004 High-throughput gene sequencing assay development for hereditary nonpolyposis colon cancer. Clin Colorectal Cancer 4: 275–279
Strom CM, Janeczko RA, Anderson B, Redman J, Quan F, Buller A, McGinniss MJ, Sun WM 2005 Technical validation of a multiplex platform to detect thirty mutations in eight genetic diseases prevalent in individuals of Ashkenazi Jewish descent. Genet Med 7: 633–639
Tutor JC 2004 Biochemical characterization of the GM2 gangliosidosis B1 variant. Braz J Med Biol Res 37: 777–783
Whitley CB, Anderson RA, McIvor RS 1992 Heterozygosity for the “DN allele” (G533-greater than A) of the beta-hexosaminidase alpha subunit gene identified by direct DNA sequencing in a family with the B1 variant of GM2-gangliosidosis. Neuropediatrics 23: 96–101
Ng PC, Henikoff S 2006 Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7: 61–80
Ramensky V, Bork P, Sunyaev S 2002 Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30: 3894–3900
Tanaka A, Ohno K, Suzuki K 1988 GM2-gangliosidosis B1 variant: a wide geographic and ethnic distribution of the specific beta-hexosaminidase alpha chain mutation originally identified in a Puerto Rican patient. Biochem Biophys Res Commun 156: 1015–1019
Teixeira CA, Sena-Esteves M, Lopes L, Sa Miranda MC, Ribeiro MG 2001 Retrovirus-mediated transfer and expression of beta-hexosaminidase alpha-chain cDNA in human fibroblasts from G(M2)-gangliosidosis B1 variant. Hum Gene Ther 12: 1771–1783
Acknowledgements
We gratefully acknowledge Patricia M. Vendely for assistance in writing and editing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by Quest Diagnostics Inc.
Rights and permissions
About this article
Cite this article
Park, N., Morgan, C., Sharma, R. et al. Improving Accuracy of Tay Sachs Carrier Screening of the Non-Jewish Population: Analysis of 34 Carriers and Six Late-Onset Patients With HEXA Enzyme and DNA Sequence Analysis. Pediatr Res 67, 217–220 (2010). https://doi.org/10.1203/PDR.0b013e3181c6e318
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/PDR.0b013e3181c6e318
